Talha Badar on Copland

Talha Badar shared a post on X:

“Copland: Targeting alternating pathway in CML/CML-AP/CML-BP.

1) MDM2i 2) BH3 mimetic 3) EZH2i

Conclusion:

• Despite potent TKIs, eliminating CML stem cells remains challenging.  
• Need better strategies to manage CML-AP/BP with poor outcomes, mOS 6-12 months.”

Source: Talha Badar/X

Dr. Talha Badar, MD, is a specialist in Hematology Oncology based in Mayo Clinic, Jacksonville, Florida. His primary areas of expertise include Leukemia, particularly Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Acute Lymphoblastic Leukemia (ALL), and Bone Marrow Transplantation. Over his career, he has actively contributed to clinical research and clinical trials.